Pharmacokinetics of fosinopril in patients with various degrees of renal function

Journal Article · Mon Apr 01 04:00:00 EST 1991 · Clinical Pharmacology and Therapeutics; (USA)

DOI:https://doi.org/10.1038/clpt.1991.54· OSTI ID:5682064

Hui, K K; Duchin, K L; Kripalani, K J; Chan, D; Kramer, P K; Yanagawa, N ^[1]

---

1. UCLA School of Medicine (USA)

Single-dose kinetics of fosinopril, a new phosphorus-containing angiotensin-converting enzyme inhibitor and its active diacid, fosinoprilat, were investigated in patients with mild, moderate, or severe renal impairment and in those with normal renal function. After an intravenous dose of {sup 14}C-fosinoprilat (7.5 mg), total body clearance of fosinoprilat was significantly greater (p less than 0.05) in patients with normal renal function than in renally impaired patients but was not related to the degree of renal impairment in patients with creatinine clearance values of 11 to 72 ml/min/1.73 m2. Decreases in renal clearance were compensated for by increases in hepatic clearance, so that total clearance was maintained. After oral {sup 14}C-fosinopril (10 mg), plasma kinetics and bioavailability of fosinoprilat were similar for the three groups of renally impaired patients. The dual elimination of fosinoprilat by the liver and the kidney distinguishes fosinopril from other angiotensin-converting enzyme inhibitors.

• OSTI ID: 5682064
• Journal Information: Clinical Pharmacology and Therapeutics; (USA), Journal Name: Clinical Pharmacology and Therapeutics; (USA) Vol. 49:4; ISSN 0009-9236; ISSN CLPTA
• Country of Publication: United States
• Language: English

Related Subjects

550901* -- Pathology-- Tracer Techniques
59 BASIC BIOLOGICAL SCIENCES
AMINES
AMINO ACIDS
AZOLES
BIOCHEMICAL REACTION KINETICS
BIOLOGICAL HALF-LIFE
BODY
CARBON 14 COMPOUNDS
CARBOXYLIC ACIDS
CLEARANCE
DISEASES
ENZYME INHIBITORS
EXCRETION
HETEROCYCLIC ACIDS
HETEROCYCLIC COMPOUNDS
ISOTOPE APPLICATIONS
KIDNEYS
KINETICS
LABELLED COMPOUNDS
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATHOGENESIS
PATIENTS
PROLINE
PYRROLES
PYRROLIDINES
REACTION KINETICS
RENAL CLEARANCE
TRACER TECHNIQUES
UROGENITAL SYSTEM DISEASES